Experimental assay NAFLD/STEA
Experimental assay Human-NAFLD/STEA 8 biopsies from steatosis patients. Samples for the STEA category were obtained in patients undergoing bariatric surgery with a BMI > 30 and subgroups defined by liver histology as follows: STEA samples had >5% fat, no inflammation, fibrosis ≤1 and ballooning ≤1.
Image data for this assay available via link to file folder containing image data for listed patient IDs (patientID in a file name)
-
Patient IDs 6610 (file names starting with h6610)
-
Patient IDs 6757 (file names starting with h6757)
-
Patient IDs 6967 (file names starting with h6967)
-
Patient IDs 7137 (file names starting with h7137)
-
Patient IDs 7251 (file names starting with h7251)
To open and visualise these files you need MOTIONTRACKING software.
SEEK ID: https://seek.lisym.org/assays/258
Experimental assay
Projects: LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI)
Investigation: Three-dimensional spatially resolved geometrical and functional models of human liver tissue
Study: Generation of 3D spatially resolved geometrical and functional models of human liver tissue
Assay position:
Assay type: Experimental Assay Type
Technology type: Technology Type
Organisms: No organisms
Export PNG
Download
Creators and Submitter
Views: 150
Created: 3rd Feb 2022 at 19:56
Last updated: 12th Jun 2024 at 14:39
TagsThis item has not yet been tagged.
Related items
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
One of the tasks of the healthy liver is to store fat. Yet, at some stage, too much fat makes the liver sick. One critical time point occurs when a healthy fatty liver becomes inflamed and progresses to steatohepatitis, or NASH. LiSyM-Pillar I will identify what events lead to this transition. Does it occur in all parts of the liver? Which molecules indicate that it is taking place? Can the degeneration be stopped or undone - and if so, how?
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research/zones-of-the-liver
Start date: 1st Jan 2016
We apply multiphoton imaging, 3D digital reconstructions and computational simulations to generate spatially-resolved geometrical and functional models of human liver tissue at different stages of non-alcoholic fatty liver disease (NAFLD).
Histopathological analysis of human biopsies. To quantitatively characterize the transition from simple STEA to eNASH, we stained, imaged and digitally reconstructed human liver tissue in 2D and 3D from biopsies of 25 patients classified into four groups: normal control (NC, n = 6), healthy obese (HO, n = 4), steatosis (STEA, n = 8) and eNASH (n = 7).
